Maravai LifeSciences Holdings

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The Protein Detection segment is engaged in manufacturing and selling labeling and visual detection reagents to scientific research customers for their tissue-based protein detection and characterization needs. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Maravai LifeSciences reports record earnings, eyes sustainable growth strategies

Maravai LifeSciences delivered strong financial performance in Q4 2022 and full year 2022, with record revenue and robust margins, supported by strategic acquisitions and diversified revenue streams.
While facing challenges such as geopolitical risks and margin fluctuations, the company is well-positioned to capitalize on growth opportunities in the cell and gene therapy market, driven by customer-centric strategies and market stability.
By focusing on sustainable growth, ESG initiatives, and customer adaptation, Maravai aims to maintain its competitive edge and drive long-term value creation for shareholders and stakeholders.
The company's commitment to innovation, market expansion, and operational efficiency underscores its resilience and potential for continued success in the evolving biotechnology landscape.

Maravai LifeSciences reports solid Q1 results amidst market challenges

Maravai LifeSciences delivered strong financial performance in Q1 2023, driven by core business strength and innovation.
While facing challenges in the biotech market and revenue decline, the company is strategically positioned for growth.
Opportunities lie in customer adoption, inorganic growth, and recovery in key markets like China.

Maravai LifeSciences adjusts revenue guidance amidst industry demand weakness

Maravai LifeSciences faces near-term challenges with revenue guidance adjustments but maintains confidence in long-term growth prospects. The company is strategically positioned in mRNA and nucleic acid chemistry, focusing on innovation and cost management strategies to drive future success.

Maravai LifeSciences reports strong Q3 earnings, eyes biotech market growth

Maravai LifeSciences Holdings reported solid Q3 performance, focusing on cost reductions and strategic investments. Despite challenges in customer conversations and limited visibility for 2024, the company remains optimistic about growth opportunities in key markets.

Maravai LifeSciences posts robust Q4 results and targets diversified growth

Maravai LifeSciences delivered strong Q4 results and expects continued growth in 2024 with a more diversified customer base.
The company's focus on innovation, efficiency, and customer commitment positions it well for future success.
While facing revenue challenges in Q1, Maravai's performance in Biologic Safety Testing segment provides stability.
Margin expansion tied to top-line growth and CleanCap technology adoption present promising opportunities for the company.

Maravai LifeSciences reports solid Q1 performance amidst growth strategies

Maravai LifeSciences Holdings navigates Q1 2024 with solid revenue, strategic partnerships, and a focus on growth and innovation.
Despite debt challenges, the company's strong cash position, cost reduction efforts, and margin improvement targets signal resilience and adaptability.
Opportunities in GMP product growth, M&A activities, and customer journey insights position Maravai for continued success and market leadership.
Addressing challenges in debt management, cost optimization, and revenue forecasting will be key to sustaining growth and profitability.

Maravai LifeSciences maintains solid financials and strategic partnerships for growth

Maravai LifeSciences demonstrates financial stability and growth potential with steady revenue guidance.
Operational successes at Flanders facilities and new product offerings enhance market competitiveness.
Challenges in managing costs and maximizing profitability require strategic decision-making.
Strategic partnerships and focus on sustainability present opportunities for market expansion and innovation.

Maravai LifeSciences reports Q3 revenue, lowers 2024 guidance, eyes acquisitions

Maravai LifeSciences Holdings faced challenges in Q3 2024 but showcased strengths in its Nucleic Acid Production segment and strategic initiatives. The company is focused on growth opportunities in mRNA technologies and expanding its product portfolio through acquisitions and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Deb Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - EVP and Chief Financial Officer Drew Burch - President, Nucleic Acid Production Conference Call Participants Dan Leonard - UBS Justin Bowers - Deutsche Bank Yuko Oku - Morgan Stanley Matt Hewitt - Craig-Hallum Dan Arias - Stifel Operator Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2024 Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research.

Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research

SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024

MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.

Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits

Repligen

Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday.

Exclusive: Repligen in bid for reagent vendor Maravai, sources say

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September.

Maravai LifeSciences Announces August and September 2024 Investor Conference Schedule

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2024 Results Conference Call August 7, 2024 5:00 PM ET Company Participants Deborah Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Chief Commercial Officer Conference Call Participants Catherine Schulte - Baird Tejas Savant - Morgan Stanley Matt Hewitt - Craig-Hallum Justin Bowers - Deutsche Bank Conor McNamara - RBC Capital Markets Michael Ryskin - Bank of America Matt Larew - William Blair Kyle Crews - UBS Operator Thank you for standing by and welcome to the Maravai LifeSciences Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2024 Earnings Call Transcript

SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024

- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth.

Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report

Applied DNA Sciences

- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability - - Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand - STONY BROOK, NY AND JUPITER, FL / ACCESSWIRE / June 20, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (NASDAQ:MRVI) and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies' previously announced Linea™ RNAP manufacturing scale-up agreement. The joint process development project resulted in an over 70% reduction in Linea RNAP manufacturing costs and the manufacture of a quantity of Linea RNAP sufficient to support Applied DNA's anticipated near-term demand for critical starting material for mRNA production.

Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.

Maravai (MRVI) Advances in RNA Research With New Collaboration

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink's leading RNA synthesis technology. TriLink's investment inclu.

TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the months of May and June.

Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Debbie Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Chief Commercial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Tejas Savant - Morgan Stanley Dan Leonard - UBS Tom Peterson - Baird Matt Larew - William Blair Bob Yan - Bank of America Securities Operator Good day, ladies and gentlemen. And welcome to the First Quarter 2024 Maravai LifeSciences Earnings Conference Call.

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2024 Earnings Call Transcript

Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation

Maravai LifeSciences Reports First Quarter 2024 Financial Results

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology.

TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production.

TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024

SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of March.

Maravai LifeSciences Announces March 2024 Investor Conference Schedule

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2023 Earnings Call Transcript

Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation

Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results

Moderna

Novavax

The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discovery to market approval is notoriously long and uncertain.

3 Doomed Biotech Stocks to Dump Before They Dive: February 2024

SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, February 22, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.

Maravai LifeSciences Announces November 2023 Investor Conference Schedule

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Deb Hart - Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Executive Vice President and Chief Commercial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tom Peterson - Baird Matt Larew - William Blair Michael Ryskin - Bank of America Conor McNamara - RBC Capital Markets Dan Arias - Stifel Justin Bowers - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by. My name is Tammy and I will be your conference operator today.

News for Maravai LifeSciences Holdings Stock (MRVI)